KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Heart Rhythm Monitoring Practices, Detection of Atrial Fibrillation, and Effect of Anticoagulation in the ARCADIA Trial.

Hooman Kamel, Mitchell S V Elkind, Richard A Kronmal, Rebeca Aragon Garcia, Pamela Plummer, Joseph P Broderick, Qi Pauls, Jordan J Elm, Marco R Di Tullio, Elsayed Z Soliman, Jeff S Healey, Shadi Yaghi, Tina M Burton, David L Tirschwell, W T Longstreth, ARCADIA Investigators

J Am Heart Assoc 14(15) e040301

PMID40728193
PMCIDPMC12449994
DOI10.1161/JAHA.124.040301
发表日期2025-07-29
入排依据:未发现恶性肿瘤人群证据。
已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other。
摘要

摘要

BACKGROUND: The ARCADIA (Atrial Cardiopathy and Antithrombotic Drugs in Prevention After Cryptogenic Stroke) trial found no benefit of anticoagulation for preventing recurrent stroke in patients with atrial cardiopathy. Data on AF monitoring across trial sites may provide context for the findings and knowledge about the current standard of care for poststroke monitoring. METHODS: At study visits, sites reported any preceding use of prolonged heart rhythm monitoring, classified as either external ambulatory monitors or implantable loop recorders. We used relative risk regression, least absolute shrinkage and selection operator (LASSO) regression, and survival analysis to explore patient characteristics associated with monitoring, the association between monitoring and AF detection, and the interaction between monitoring and study treatment effect on recurrent stroke. RESULTS: Of 1633 patients with monitoring data, 957 (58.6%) underwent prolonged monitoring: 567 (34.7%) external ambulatory monitor, 479 (29.3%) implantable loop recorder, and 89 (5.5%) both. The strongest predictors of monitoring were Hispanic ethnicity (standardized LASSO coefficient, -0.19 [risk ratio (RR), 0.66]), National Institutes of Health Stroke Scale score (LASSO, -0.15 [RR per point, 0.97]), left atrial diameter (LASSO, 0.13 [RR per cm, 1.09]), and serum hemoglobin (LASSO, -0.12 [RR per g/dL, 0.97]). At the site level, the median proportion of patients who underwent monitoring was 63% (interquartile range, 36%-92%). The site-level proportion of patients with an implantable loop recorder was associated with greater likelihood of AF detection (RR, 3.9 [95% CI, 2.1-7.4]) but did not modify the trial treatment effect (P value for interaction, 0.99). CONCLUSIONS: In the ARCADIA trial, which enrolled patients with cryptogenic stroke across the United States and Canada, nearly 60% of patients underwent prolonged heart rhythm monitoring. Use of implantable loop recorders was associated with greater likelihood of AF detection.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. Flow diagram of patients included in analysis of heart rhythm monitoring practices in the ARCADIA trial. Prolonged heart rhythm monitoring was defined as external ambulatory monitors or implantable loop recorders. Baseline monitoring data refers to data on heart rhythm monitoring before randomization in the trial. A total of 116 patients had prolonged monitoring both before and after randomization. Patients with AF detected at baseline were no longer eligible for randomization, but 14 such patients included in this analysis were randomized in the trial in error. Most AF diagnoses (112/177 [65.9%]) were documented to have been made via prolonged heart rhythm monitoring. AF indicates atrial fibrillation; and ARCADIA, Atrial Cardiopathy and Antithrombotic Drugs in Prevention After Cryptogenic Stroke.
非 KM Figure
Figure 2Figure 2. Distribution across sites of the proportion of patients undergoing prolonged heart rhythm monitoring. Only sites with >10 patients in this sample are shown (96 sites had ≤10 patients and 55 had >10 patients).
非 KM Figure
Figure 3Figure 3. Relationship between site‐level proportion of patients undergoing prolonged heart rhythm monitoring and detection of atrial fibrillation. The red line represents the result of a LOWESS regression analysis of the association between site‐level heart rhythm monitoring and the probability of atrial fibrillation diagnosis. LOWESS indicates locally weighted scatterplot smoothing.
非 KM Figure